Measuring Facebook: Chinwag Insight 2011

Chinwag Insight: Facebook Marketing View more presentations from Market Sentinel. Earlier this month we presented on the measurement and monetisation panel at the Chinwag Insight: Facebook Marketing conference. You can view our slides above or by visiting Slideshare. My slides focused on the challenges of Facebook from a data perspective: Facebook is difficult to measure, and what little data there is suggests that brands are really struggling to engage with Continue reading

Facebook’s F8: Where will it leave brands?

This week there’s been a lot of buzz and debate around our latest Skyttle Friends research suggesting that brands are not doing as well on Facebook as they appear to be (Can Facebook Work For Brands?). Both Econsultancy and Social Media Today have cited our work, adding emphasis to the results: EConsultancy‘s Patricio Robles: “…this discussion harbors a crucial point: it isn’t enough to rack up the ‘likes'; if those Continue reading

Can Facebook Work For Brands? [UPDATE 3]

All this summer we have been looking at the effectiveness of Facebook for a variety of big brand customers. Here is what we have discovered, and for Facebook it doesn’t make pretty reading. Facebook ads don’t work for brands Even with the ability of the user to determine how and to whom an ad is served with great demographic accuracy, Facebook ads have click-through rates of only 0.011-0.165%, compared to Continue reading

Measuring Outcomes in Facebook Marketing: IAB Event Recap

It was an honour and a thrill to sponsor last night’s IABUK’s Social Media Event – How to keep the party going – held at the LBi offices on Brick Lane. The event had a great turnout and featured some incredible talks by folks from Torchbox, LinkedIn, Bing and Skive to name a few. Our own Mark Rogers was also speaking on Measuring Outcomes in Facebook Marketing, where our Squishable Continue reading

New Facebook Rules: A Challenge and an Opportunity for Pharma

Our latest white paper explores how pharmaceutical companies can manage and benefit from Facebook in light of Facebook’s new policy to require open comments. Yesterday, Pharmalot reported that some drugmakers may abandon Facebook if they can’t cope with the changes. They interviewed several drugmakers about their plans, including Sanofi and AstraZeneca, who acknowledge that they may walk away from Facebook if they cannot overcome concerns posed by the new policy. Continue reading